Acelyrin Inc [SLRN] stock is trading at $7.00, up 4.01%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SLRN shares have gain 7.53% over the last week, with a monthly amount glided 81.35%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Acelyrin Inc [NASDAQ: SLRN] stock has seen the most recent analyst activity on July 08, 2024, when Wells Fargo upgraded its rating to a Overweight but kept the price target unchanged to $13 for it. Previously, Wells Fargo started tracking the stock with Equal Weight rating on December 13, 2023, and set its price target to $11. On December 08, 2023, Citigroup initiated with a Neutral rating and assigned a price target of $8 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight but stick to its price target of $19 on September 13, 2023. H.C. Wainwright initiated its recommendation with a Buy and recommended $44 as its price target on September 05, 2023. In a note dated May 30, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $68 on this stock.
Acelyrin Inc [SLRN] stock has fluctuated between $3.67 and $29.88 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Acelyrin Inc [NASDAQ: SLRN] shares were valued at $7.00 at the most recent close of the market. An investor can expect a potential return of 85.71% based on the average SLRN price forecast.
Analyzing the SLRN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.56 and Total Capital is -0.5. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.77 points at the first support level, and at 6.53 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.17, and for the 2nd resistance point, it is at 7.33.
Ratios To Look Out For
For context, Acelyrin Inc’s Current Ratio is 13.27. In addition, the Quick Ratio stands at 13.27 and the Cash Ratio stands at 5.06.
Transactions by insiders
Recent insider trading involved Becker Daniel J., Director, that happened on Jul 17 ’24 when 1.0 shares were sold. Chief Executive Officer, Lin Shao-Lee completed a deal on Apr 01 ’24 to sell 9961.0 shares. Meanwhile, Chief Executive Officer Lin Shao-Lee sold 15701.0 shares on Feb 20 ’24.
